Pramlintide Side Effects: Safety Signals and Warnings
Pramlintide safety concerns are compound-specific. The main listed side effects are Nausea (most common, usually transient), Headache, and Anorexia. The main warning signals are Boxed warning: Severe hypoglycemia risk, particularly in type 1 diabetes - always reduce mealtime insulin dose by 50% when initiating pramlintide, Should not be used in patients with hypoglycemia unawareness, and Contraindicated in patients with gastroparesis.
Direct Answer
Pramlintide (Symlin) is FDA-approved as an adjunct to insulin in both type 1 and type 2 diabetes, with multiple Phase 3 RCTs supporting meaningful HbA1c and postprandial glucose reduction. Its amylin-mimetic mechanism is distinct from GLP-1 agonism. In combination with GLP-1 agents, amylin agonism shows additive weight-loss effects. A well-validated compound with a real regulatory record.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Weight Loss & Metabolic
- Best for
- Insulin-adjunct glycemic control, postprandial glucose management, amylin pathway research
Reported Side Effects
- Nausea (most common, usually transient)
- Headache
- Anorexia
- Vomiting
- Abdominal pain
- Injection site reactions
- Hypoglycemia (when used with insulin)
Warnings
- Boxed warning: Severe hypoglycemia risk, particularly in type 1 diabetes - always reduce mealtime insulin dose by 50% when initiating pramlintide
- Should not be used in patients with hypoglycemia unawareness
- Contraindicated in patients with gastroparesis
- Not a substitute for insulin
- Should not be mixed with insulin in the same syringe
Known or Plausible Interactions
- Insulin (increased hypoglycemia risk - mandatory insulin dose reduction)
- Oral medications requiring rapid absorption (delayed gastric emptying may slow absorption)
- Alpha-glucosidase inhibitors (additive effects on GI motility)
- Anticholinergics (may counteract gastric motility effects)
Regulatory Context
FDA approved (2005, Symlin). Prescription required. Not a controlled substance.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Postprandial Glucose Control (Level A), Body Weight (Level A), and Glucagon Suppression (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Pramlintide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/pramlintide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.